Board of Directors

Peter Hammond - Chairman

Peter Hammond is a co-founder and principal of Exto Partners Pty Ltd, a boutique venture capital and corporate finance firm based in Sydney. With over 13 years' experience in financial management, venture capital and corporate finance, Peter has advised biotechnology, financial services, manufacturing, consumer services and technology companies in Australia and USA. Peter has assisted companies through a wide range of growth paths and transitions, including early stage financing, the bringing of new products to global markets to large-scale mergers. As a Principal of Exto Partners, Peter assists clients with capital raising, strategic business planning and development, financial and operational management, and corporate governance. Peter is an experienced company director. He sits on the Board of Directors for a number of Exto Partners' portfolio companies and is a member of the Institute of Chartered Accountants and has a BBus. from the University of Technology, Sydney.

Dr Barry Marshall - Executive Director

Dr Marshall is a world authority on Helicobacter pylori. He is the co-discoverer of the H. pylori organism, co-recipient of the 2005 Nobel Prize for Medicine and Physiology as well as numerous other prestigious awards (including the 1995 Lasker Award) and elected a Fellow of the Royal Society in 1999 and US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discovery has revolutionised the management of peptic ulcer disease and resulted in the cure for peptic ulcers. Related research into a diagnostic leading to patentable technology resulted in the formation of TriMed Distributors Pty Ltd, a successful private company.

Dr Marshall is the founder of Ondek. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.

Lars Molinder - Non Executive Director

Lars Molinder is currently the Group Head of the Healthcare Sector at Carnegie Investment Bank in Sweden. He has over 15 years of financial sector experience working solely with companies in the healthcare sector. Lars has been the Head of Medicine and Biotechnology at the Swedish Industrial Development Fund and made over 40 investments in early stage companies ranging from medical technology and diagnostics to pharmaceuticals and biotechnology. Prior to joining Carnegie Investment Bank, Lars was the Nordic Head of Healthcare Sector and European co-Head of Healthcare Banking at Alfred Berg and ABN AMRO. He is on the Board of Directors of Bioinvent and Karo Bio, both listed on the Stockholm Stock Exchange. Selected recent deals include: defence adviser to Gambro (PTP) and Biacore (PTP), and sole lead manager for the initial public offering of Clavis Pharma, Orexo and Biovitrum. Lars has a M.Sc. in Engineering.

Dr Neil Weir - Non Executive Director

Neil is Senior Vice-President, Discovery UCB S.A., responsible for global discovery at UCB, overseeing an integrated portfolio of small molecule and antibody therapeutic projects in the areas of Immunology and Neurology. The discovery team Neil is responsible for has transitioned twenty novel molecules into development, comprising small molecules and antibodies, Neil was one of the inventors of the drug Cimzia®, a novel pegylated anti-TNF. Prior to his role at UCB, Neil was head of Discovery at Celltech R and D in the UK during which time he was involved in the discovery and development of antibody and antibody fragment-based drugs.

Neil is a member of the Research Directors Group of EFPIA (The European Federation of Pharmaceutical Industries and Associations) and has sponsored three call topics in the European Innovative Medicines Initiative (IMI). He is a member of the MRC Translational Research Group and the HealthTech and Medicines KTN Steering Board, a member of the MRC's Stratified Medicine Steering Group and chair of the industry advisory panel for UCL vision course for senior executive training for the BioIndustries.

Neil received a BSc (Hons) in biology from Edinburgh University and a PhD at the Institute of Biotechnology (University of Kent at Canterbury) studying metabolic flux through amino acid biosynthesis pathways.

William Jeffrey Veling - Non Executive Director

Dr Jeff Veling is an actively practising medical practitioner in family medicine. He is also involved with medical student teaching. He has a hospital accreditation and up until recently also practised obstetrics. Dr Veling trained in Western Australia.